Eli Lilly and Company (NYSE:LLY) Shares Purchased by JPL Wealth Management LLC

JPL Wealth Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 38.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 783 shares of the company’s stock after buying an additional 216 shares during the period. JPL Wealth Management LLC’s holdings in Eli Lilly and Company were worth $709,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Massachusetts Wealth Management lifted its position in shares of Eli Lilly and Company by 35.1% during the second quarter. Massachusetts Wealth Management now owns 2,215 shares of the company’s stock worth $2,005,000 after purchasing an additional 575 shares in the last quarter. Valmark Advisers Inc. lifted its position in shares of Eli Lilly and Company by 2.6% during the second quarter. Valmark Advisers Inc. now owns 5,736 shares of the company’s stock worth $5,193,000 after purchasing an additional 146 shares in the last quarter. Retireful LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $1,048,000. SeaBridge Investment Advisors LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $206,000. Finally, Obermeyer Wood Investment Counsel Lllp increased its stake in shares of Eli Lilly and Company by 1,772.2% in the second quarter. Obermeyer Wood Investment Counsel Lllp now owns 14,903 shares of the company’s stock worth $13,493,000 after buying an additional 14,107 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Barclays lifted their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Truist Financial reiterated a “buy” rating and set a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $961.76.

Eli Lilly and Company Price Performance

LLY stock traded up $19.82 during trading on Friday, hitting $960.02. The company had a trading volume of 2,555,073 shares, compared to its average volume of 3,625,430. The firm has a market capitalization of $912.43 billion, a price-to-earnings ratio of 141.39, a P/E/G ratio of 2.91 and a beta of 0.41. The business has a 50 day moving average of $892.64 and a 200 day moving average of $822.08. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 192,794 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the sale, the insider now directly owns 98,208,810 shares of the company’s stock, valued at $81,490,724,273.70. The disclosure for this sale can be found here. In the last three months, insiders sold 1,097,883 shares of company stock valued at $972,022,568. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.